tetano
Editor, Senior Moderator
Sci Rep. 2017 Aug 25;7(1):9500. doi: 10.1038/s41598-017-10021-w.
[h=1]Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction.[/h] Watanabe K[SUP]1[/SUP], Ishikawa T[SUP]2[/SUP], Otaki H[SUP]2[/SUP], Mizuta S[SUP]2[/SUP], Hamada T[SUP]3[/SUP], Nakagaki T[SUP]2[/SUP], Ishibashi D[SUP]2[/SUP], Urata S[SUP]4[/SUP], Yasuda J[SUP]4[/SUP], Tanaka Y[SUP]2[/SUP], Nishida N[SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus infections are serious public health concerns throughout the world. The development of compounds with novel mechanisms of action is urgently required due to the emergence of viruses with resistance to the currently-approved anti-influenza viral drugs. We performed in silico screening using a structure-based drug discovery algorithm called Nagasaki University Docking Engine (NUDE), which is optimised for a GPU-based supercomputer (DEstination for Gpu Intensive MAchine; DEGIMA), by targeting influenza viral PA protein. The compounds selected by NUDE were tested for anti-influenza virus activity using a cell-based assay. The most potent compound, designated as PA-49, is a medium-sized quinolinone derivative bearing a tetrazole moiety, and it inhibited the replication of influenza virus A/WSN/33 at a half maximal inhibitory concentration of 0.47 μM. PA-49 has the ability to bind PA and its anti-influenza activity was promising against various influenza strains, including a clinical isolate of A(H1N1)pdm09 and type B viruses. The docking simulation suggested that PA-49 interrupts the PA-PB1 interface where important amino acids are mostly conserved in the virus strains tested, suggesting the strain independent utility. Because our NUDE/DEGIMA system is rapid and efficient, it may help effective drug discovery against the influenza virus and other emerging viruses.
PMID: 28842649 DOI: 10.1038/s41598-017-10021-w
[h=1]Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction.[/h] Watanabe K[SUP]1[/SUP], Ishikawa T[SUP]2[/SUP], Otaki H[SUP]2[/SUP], Mizuta S[SUP]2[/SUP], Hamada T[SUP]3[/SUP], Nakagaki T[SUP]2[/SUP], Ishibashi D[SUP]2[/SUP], Urata S[SUP]4[/SUP], Yasuda J[SUP]4[/SUP], Tanaka Y[SUP]2[/SUP], Nishida N[SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus infections are serious public health concerns throughout the world. The development of compounds with novel mechanisms of action is urgently required due to the emergence of viruses with resistance to the currently-approved anti-influenza viral drugs. We performed in silico screening using a structure-based drug discovery algorithm called Nagasaki University Docking Engine (NUDE), which is optimised for a GPU-based supercomputer (DEstination for Gpu Intensive MAchine; DEGIMA), by targeting influenza viral PA protein. The compounds selected by NUDE were tested for anti-influenza virus activity using a cell-based assay. The most potent compound, designated as PA-49, is a medium-sized quinolinone derivative bearing a tetrazole moiety, and it inhibited the replication of influenza virus A/WSN/33 at a half maximal inhibitory concentration of 0.47 μM. PA-49 has the ability to bind PA and its anti-influenza activity was promising against various influenza strains, including a clinical isolate of A(H1N1)pdm09 and type B viruses. The docking simulation suggested that PA-49 interrupts the PA-PB1 interface where important amino acids are mostly conserved in the virus strains tested, suggesting the strain independent utility. Because our NUDE/DEGIMA system is rapid and efficient, it may help effective drug discovery against the influenza virus and other emerging viruses.
PMID: 28842649 DOI: 10.1038/s41598-017-10021-w